The primary focus of the Lung Cancer Issue series is the well-known driver mutations in lung adenocarcinomas, not only EGFR and EML4-ALK but also the more recently identified ROS1 and RET. Other druggable mutations, such as HER2, are also explained, as well as the new promise of FGFR1 in squamous cell carcinoma of the lung. Methodologies for developing drugs for the numerous newly revealed driver mutations are also discussed in these issues.
Our Guest Editors for the issue series is Dr. Rafael Rosell and Dr. Niki Karachaliou from Spain. With the issue, we aim to provide practical information epitomizing the rapid progress in the field of lung cancer today and instilling in physicians the confidence derived from this knowledge when dealing with patients. Please follow up on this issue to learn the updated techniques and researches for lung cancer.
